Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
Chr del(11q)
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
ibrutinib
Sensitive: A2 - Guideline
ibrutinib
Sensitive
:
A2
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
rituximab
Resistant: A2 - Guideline
rituximab
Resistant
:
A2
rituximab
Resistant: A2 - Guideline
rituximab
Resistant
:
A2
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
obinutuzumab + acalabrutinib
Sensitive
:
A2
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
obinutuzumab + acalabrutinib
Sensitive
:
A2
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
ibrutinib + ublituximab-xiiy
Sensitive: B - Late Trials
ibrutinib + ublituximab-xiiy
Sensitive
:
B
ibrutinib + ublituximab-xiiy
Sensitive: B - Late Trials
ibrutinib + ublituximab-xiiy
Sensitive
:
B
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
obinutuzumab
Resistant: B - Late Trials
obinutuzumab
Resistant
:
B
obinutuzumab
Resistant: B - Late Trials
obinutuzumab
Resistant
:
B
Chr del(11q)
Small Lymphocytic Lymphoma
Chr del(11q)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: B - Late Trials
ibrutinib
Sensitive
:
B
ibrutinib
Sensitive: B - Late Trials
ibrutinib
Sensitive
:
B
Chr del(11q)
Small Lymphocytic Lymphoma
Chr del(11q)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
acalabrutinib
Sensitive: B - Late Trials
acalabrutinib
Sensitive
:
B
acalabrutinib
Sensitive: B - Late Trials
acalabrutinib
Sensitive
:
B
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
venetoclax + ibrutinib
Sensitive: C2 – Inclusion Criteria
venetoclax + ibrutinib
Sensitive
:
C2
venetoclax + ibrutinib
Sensitive: C2 – Inclusion Criteria
venetoclax + ibrutinib
Sensitive
:
C2
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
lenalidomide + tafasitamab-cxix
Sensitive: C3 – Early Trials
lenalidomide + tafasitamab-cxix
Sensitive
:
C3
lenalidomide + tafasitamab-cxix
Sensitive: C3 – Early Trials
lenalidomide + tafasitamab-cxix
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
RP6530
Sensitive: C3 – Early Trials
RP6530
Sensitive
:
C3
RP6530
Sensitive: C3 – Early Trials
RP6530
Sensitive
:
C3
Chr del(11q)
Small Lymphocytic Lymphoma
Chr del(11q)
Small Lymphocytic Lymphoma
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
Chr del(11q)
Multiple Myeloma
Chr del(11q)
Multiple Myeloma
obinutuzumab
Resistant: C3 – Early Trials
obinutuzumab
Resistant
:
C3
obinutuzumab
Resistant: C3 – Early Trials
obinutuzumab
Resistant
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
duvelisib
Sensitive: C3 – Early Trials
duvelisib
Sensitive
:
C3
duvelisib
Sensitive: C3 – Early Trials
duvelisib
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
FCR
Sensitive: C3 – Early Trials
FCR
Sensitive
:
C3
FCR
Sensitive: C3 – Early Trials
FCR
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
ibrutinib + UC-961
Sensitive: C3 – Early Trials
ibrutinib + UC-961
Sensitive
:
C3
ibrutinib + UC-961
Sensitive: C3 – Early Trials
ibrutinib + UC-961
Sensitive
:
C3
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
Compound C
Sensitive: D – Preclinical
Compound C
Sensitive
:
D
Compound C
Sensitive: D – Preclinical
Compound C
Sensitive
:
D
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
hydroxychloroquine
Sensitive: D – Preclinical
hydroxychloroquine
Sensitive
:
D
hydroxychloroquine
Sensitive: D – Preclinical
hydroxychloroquine
Sensitive
:
D
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
MRT68921
Sensitive: D – Preclinical
MRT68921
Sensitive
:
D
MRT68921
Sensitive: D – Preclinical
MRT68921
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login